5:35 PM
Oct 30, 2012
 |  BC Extra  |  Company News

BioXpress, AET BioTech to co-develop adalimumab biosimilar

BioXpress Therapeutics S.A. (Plan-les-Ouates, Switzerland) and AET BioTech partnered to co-develop a biosimilar version of autoimmune drug adalimumab, a human mAb against tumor necrosis factor (TNF) alpha....

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >